Retatrutide

1. Quick Facts

Category: Triple Agonist Metabolic Peptide

Risk Level: High

Research Status: Phase 3 Clinical Trials

Administration: Subcutaneous Injection

Typical Frequency: Weekly

Estimated Half-Life: Approximately 6 Days

Primary Research Interest: Weight Loss / Appetite Suppression / Metabolic Health

Important Disclaimer

This material is provided strictly for educational and informational purposes related to peptide research and metabolic compounds. Retatrutide is a potent biologically active triple agonist peptide capable of significantly altering glucose regulation, appetite signaling, gastrointestinal function, and metabolic pathways. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.

2. Summary

Retatrutide is an investigational triple agonist peptide designed to simultaneously target glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. It is being studied as a next-generation metabolic therapy capable of influencing appetite regulation, energy expenditure, glucose control, and body composition.

Research interest in Retatrutide primarily centers around obesity, metabolic dysfunction, weight management, and cardiometabolic health. Early clinical studies have demonstrated substantial reductions in body weight, leading to significant interest within obesity and metabolic medicine research.

What People Commonly Claim

More effective weight loss than earlier GLP-1 medications
Powerful appetite suppression
Improved blood sugar regulation
Enhanced fat loss through increased energy expenditure
Potentially superior body composition outcomes compared with single-receptor therapies

What the Literature Actually Shows

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously.
Clinical studies have demonstrated substantial dose-dependent weight reduction.
Research suggests improvements in metabolic markers, glucose regulation, and liver fat content.
Gastrointestinal side effects remain common and often increase with dose escalation.
Retatrutide remains investigational and has not yet received broad regulatory approval for obesity treatment.

3. Reconstitution Guide

Vial Size: 60 mg
Dilutant Type: BAC Water
Amount of Dilutant Added: 3 mL
Final Concentration: 20.00 mg/mL

At this concentration:
• 1 mg = 0.050 mL (5.0 units)
• 2 mg = 0.100 mL (10.0 units)
• 4 mg = 0.200 mL (20.0 units)
• 6 mg = 0.300 mL (30.0 units)
• 12 mg = 0.600 mL (60.0 units)

*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.

4. Route of Administration

Retatrutide is most commonly administered as a subcutaneous injectable metabolic peptide.

Primary Route: SubQ Injection
Preferred Timing: Flexible weekly administration timing
Administration Notes: Gradual dose-escalation schedules are commonly utilized in research settings to improve tolerability and reduce gastrointestinal side effects.

5. Common Research Protocols

Product Strength: 20.00 mg/mL
Typical Delivered Amount: Weeks 1–4: 1–2 mg weekly; Weeks 5–8: 2–4 mg weekly; Weeks 9–12: 4–6 mg weekly; Advanced research ranges commonly investigate 6–12 mg weekly
Frequency: Weekly
Cycle Length: Long-term administration is commonly investigated; study durations have ranged from several months to over one year
Special Notes: Retatrutide is unique among currently studied metabolic peptides due to its simultaneous activation of GLP-1, GIP, and glucagon receptors. Slow titration schedules are commonly emphasized to improve tolerability.

6. Mechanism of Action

Retatrutide functions through simultaneous activation of three metabolic hormone receptor systems.

The peptide combines pathways that influence appetite regulation, insulin signaling, energy expenditure, and fat metabolism.

Potential downstream effects discussed in the literature include:

GLP-1 receptor activation supporting appetite suppression and delayed gastric emptying
GIP receptor activation influencing insulin secretion and metabolic regulation
Glucagon receptor activation promoting energy expenditure and fat metabolism signaling
Reduced caloric intake
Improved glucose regulation
Enhanced fat-loss signaling
Potential increases in metabolic expenditure

7. Potential Benefits

Potential substantial body fat reduction
Powerful appetite suppression
Improved glucose regulation
Enhanced metabolic health markers
Potential improvements in insulin sensitivity
Possible reduction in liver fat accumulation
Potential cardiovascular risk-factor improvement

8. Potential Risks / Side Effects

High

Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort
Severe appetite suppression
Potential lean-mass loss during aggressive weight reduction
Gallbladder complications
Pancreatitis concerns
Potential hypoglycemia risk in susceptible individuals

9. Half-Life

Retatrutide is commonly reported to have an estimated half-life of approximately 6 days.

This extended duration supports once-weekly administration protocols and contributes to relatively stable circulating levels between doses.

10. Storage Information

Store refrigerated before and after reconstitution
Protect from direct light exposure
Avoid repeated freeze-thaw cycles
Maintain sterile handling practices during preparation

11. Contraindications / Warnings

History of pancreatitis
Gallbladder disease
Pregnancy or breastfeeding
Severe gastrointestinal disorders
Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2 (MEN2)

12. Further Study

13. Research References

PubMed
PubMed Central (PMC)
NIH Publications
Peer-reviewed endocrinology journals
Metabolic peptide research literature
Obesity medicine clinical trial data

14. Last Reviewed

June 2026

RT30: 20-100-500